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codon83 (Serine83Arginine) was noted in 1 strain having a
CIP MIC of 0.012 and a NA MIC of 32g/ml. All 28 strains
that had a CIP MIC of 0.016—1.5g/ml and frank resis-
tance to NA (MIC ≥16g/ml; DD zone of inhibition ≤13mm)
carried a transversion mutation in codon 83 of gyrA (Ser-
ine83Isoleucine). We noted another transversion mutation in
codon 85 of parC (Serine85Leucine) in 14 of these 28 strains
that had a CIP MIC of ≥0.125—1.5 and a NA MIC ≥256g/ml).
We could not detect any mutations in gyrB (n = 24) and parE
(n = 28) genes.
Conclusion: Reduced CIP-susceptibility and NA-resistance
of V. cholerae is associated with a gyrA mutation (Ser-
ine83Isoleucine). A further decrease in CIP-susceptibility is
associated with parC mutation (Serine85Leucine).
doi:10.1016/j.ijid.2008.05.284
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Background:Organisms producing extended-spectrum ˇ-
lactamases(ESBL) are emerging around the world as a source
of resistance to oxyiminocephalosporins such as cefotaxime,
ceftazidime and ceftrioxone.This study was undertaken to
study the prevalence of ESBL production by Klebsiella spp.
in an urban hospital in South India.
Methods:Antimicrobial susceptibility testing of 213
strains of Klebsiella spp. isolated from various clinical speci-
mens was carried out by disc diffusionmethod.One hundered
and ﬁve strains found to be resistant to at least one of
the third generation cepholosporins tested, viz, cefotoxime,
ceftazidime and ceftrioxone were screened for the pro-
duction of ESBL by phenotypic and genotypic methods.The
phenotypic methods include the phenotypic conﬁrmatory
disc diffusion test (PCDDT)and double disc diffusion syn-
ergy test(DDST)and the genotypic method include the PCR
ampliﬁcation method.
Results:Of the 105 strains screened for ESBL producton
45(42.85%)and 43(40.95%) strains were positive by PCDDT
and DDST methods respectively and 53(50.47%)strains were
positive by genotypic method.
Conclusion:The prevalence of ESBL produced by Kleb-
siella spp. from various clinical conditions in this part of the
country is 24.88% as detected by the genotypic method.The
study suggests that ESBL production should be detected rou-
tinely to monitor the resistant organisms for implementation
of appropriate infection control measures.
doi:10.1016/j.ijid.2008.05.285
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Background: Since ﬁrst reported in Germany in 1983
and in the United States in 1989, extended-spectrum ˇ-
lactamases (ESBLs) have spread worldwide. These enzymes
are mostly plasmid-encoded derivatives of TEM-1, TEM-2,
and SHV-1 by one or more base pair changes or are from a
rapidly evolving class called CTX-M.
Methods: K. pneumoniae ML2011 was collected on July
2004, from intensive care unit of Military hospital in Tunisia.
Identiﬁcation of strains was performed by using both API
20 E and the VITEK automated system. Minimal inhibitory
concentrations (MICs) were determined by E-test Strips
for the strain on Mueller-Hinton agar as recommended
by the Clinical and Laboratory Standards Institute (CLSI)
(CLSI/National Committee for Clinical Laboratory Stan-
dards [NCCLS], 2006). Transfer of resistance phenotypes
was performed by transformation and conjugation exper-
iments. The ESBL was identiﬁed by double-disk synergy
test, by isoelectric focusing and sequencing of PCR prod-
ucts.
Results: MICs for K. pneumoniae ML2011 showed
that this strain was resistant to all ˇ-lactams tested
expect imipenem. K. pneumoniae ML20011 exhibited a
high level of resistance to oxyimino cephalosporins.
The strain was also resistant to kanamycin, chloram-
phenicol, ciproﬂoxacin, nalidixic acid, tetracycline and
streptomycin. The disk diffusion method showed synergy
between ceftazidime, cefotaxime, aztreonam, ceftriaxon,
and amoxicillin-clavulanic acid against the strain and its
transformants and transconjugants, suggesting plasmid-
mediated production of an ESBL enzyme. PCR analyses
conﬁrmed the presence of blaSHV in parent strain K. pneu-
moniae ML2011, and its transformants E. coli DH5˛/pML2011
and transconjugants E. coli HB101 X pML2011 indicating
that this gene is located on transferable plasmid with esti-
mated molecular size of 50 kb. Nucleotide sequence was
performed on the coding region 861pb used to predict
the amino acid sequence. This sequence was compared
with strain K. pneumoniae Kp297 (DDBJ/EMBL/GeneBank
accession no. EF035567) for nucleotide sequence homol-
ogy and predicted amino sequence. Two amino acid
substitutions were found at position 5 and 202, result-
ing respectively in a Met (ATG) to Leu (TTG) and an
Arg (CGT) to Ser (AGT) changes. As theses substitu-
tions not showed by other known SHV ˇ-lactamases,
the pI 7.3 from K. pneumoniae ML2011 appears to
be a novel ESBL and has been designated SHV-104
(http://www.lahey.org).
